Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | ATM | Q13315 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805013 | 0.79 | KDM4E (0.42) | L3MBTL1TSHRKDM4EKMT2AMAPT | |
| SCHEMBL17848973 | 0.78 | TDP1 (0.52) | L3MBTL1TSHRKDM4EMEN1KMT2A | |
| SCHEMBL789181 | 0.78 | KDM4E (0.51) | L3MBTL1TSHRKDM4EMEN1KMT2A | |
| SCHEMBL805040 | 0.78 | KDM4E (0.53) | L3MBTL1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL805001 | 0.78 | KDM4E (0.53) | L3MBTL1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL804981 | 0.77 | TSHR (0.61) | L3MBTL1TSHRKDM4EMEN1KMT2A | |
| SCHEMBL804765 | 0.77 | MAPT (0.43) | L3MBTL1TSHRKDM4EMEN1KMT2A | |
| SCHEMBL10111723 | 0.77 | MAPT (0.43) | L3MBTL1TSHRKDM4EMEN1KMT2A | |
| SCHEMBL13956255 | 0.76 | L3MBTL1 (0.50) | L3MBTL1TSHRKDM4EMEN1KMT2A | |
| SCHEMBL805106 | 0.76 | KDM4E (0.46) | TSHRKDM4EHPGDPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2018-06-14 | — | — | US | disclosed |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | PREP, PRSS1, PEPD | L3MBTL1 3087/4885TSHR 4670/4885KDM4E 1290/4885 |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | L3MBTL1 3087/4885TSHR 4670/4885KDM4E 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.